A wish list for molecular tests.

  title={A wish list for molecular tests.},
  author={Bob Carlson},
  journal={Biotechnology healthcare},
  volume={4 6},
Companion diagnostics improve health outcomes, say developers, who are willing to work with payers to develop medical policies for coverage. Payers and clinicians want more evidence of long-term benefit. The FDA, meanwhile, is jostling for regulatory control. How long will patients have to wait? Part 2 of 2.